All In Biotech

Drug Trial Radar · NCT05735184

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia

Last checked: Nov 21, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Jul 18, 2023

Primary completion

Apr 2030

Study completion Apr 2030

Sponsor

Lead sponsor
Kura Oncology, Inc.Industry
Sponsor type
Industry
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion. The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.

Conditions

  • Acute Myeloid Leukemia
  • Mixed Lineage Leukemia Gene Mutation
  • Refractory AML
  • AML With Mutated NPM1
  • Acute Myeloid Leukemia Recurrent
  • Acute Myeloid Leukemia, in Relapse
  • NPM1 Mutation
  • KMT2Ar
  • Myeloid Sarcoma
  • Nucleophosmin 1-mutated Acute Myeloid Leukemia

Interventions

  • ZiftomenibDrug

    Oral Administration

  • VenetoclaxDrug

    Oral Administration

  • AzacitidineDrug

    Subcutaneous or Intravenous Administration

  • DaunorubicinDrug

    Intravenous Administration

  • CytarabineDrug

    Intravenous Administration

  • QuizartinibDrug

    Oral Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of dose limiting toxicities (DLTs) per dose level (Part 1a only)Time frame: During the first 28 days of ziftomenib in combination with SOC backbone treatment (1 cycle)
  2. Descriptive statistics of adverse eventsTime frame: From Cycle 1 Day 1 up to and including 28 days following the end of 36 months of treatment
  3. Complete remission (CR) rateTime frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic - Phoenix

    Phoenix, Arizona · Recruiting

  • Moores UC San Diego Cancer Center

    La Jolla, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA - Bowyer Oncology Center

    Los Angeles, California · Recruiting

  • UC Irvine Health Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Yale Cancer Center and Smilow Cancer Hospital

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Emory Healthcare - The Emory Clinic

    Atlanta, Georgia · Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois · Recruiting

  • Loyola University Medical Center

    Maywood, Illinois · Recruiting

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa · Recruiting

  • The University of Kansas Medical Center Research Institute

    Fairway, Kansas · Recruiting

  • University of Kentucky Markey Cancer Center

    Louisville, Kentucky · Recruiting

  • Norton Cancer Institute - St. Matthews

    Louisville, Kentucky · Recruiting

  • Ochsner MD Anderson Cancer Center

    Jefferson, Louisiana · Recruiting

  • Johns Hopkins School of Medicine

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • UMass Chan Medical School

    Worcester, Massachusetts · Recruiting

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • New York - Presbyterian / Weill Cornell Medicine

    New York, New York · Recruiting

  • Mount Sinai - Ruttenberg Treatment Center

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Stony Brook University Hospital

    Stony Brook, New York · Recruiting

  • Duke Blood Cancer Center

    Durham, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic Taussig Cancer Institute

    Cleveland, Ohio · Recruiting

  • The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • TriStar Bone Marrow Transplant

    Nashville, Tennessee · Recruiting

  • Sarah Cannon Research Institute - St. David's South Austin Medical Center / Texas Oncology South Austin

    Austin, Texas · Recruiting

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.